Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

NOKOMIS, Fla.--(BUSINESS WIRE)--

Research into Cancer Stem Cells (CSC) is on the rise, fueling industry growth that Rainbow Coral Corp. (OTCBB: RBCC.OB - News) expects to translate into demand for n3D cell growth technologies.

RBCC is finalizing an equity funding agreement with n3D Biosciences, the maker of a revolutionary new system that allows scientists to grow three-dimensional cell cultures more easily than ever before. The device, called the Bio-Assembler, could have an extraordinary impact on cell research worldwide, and RBCC expects to find a strong market for the device once its funding agreement with n3D is finalized.

Many cancers, including breast, prostate, pancreatic, colon, brain, and lung cancers, contain a subset of stem-like cells understood to play a critical role in the development and progression of the disease. Research suggests that these cells, called Cancer Stem Cells, are able to “seed” new tumor formation and drive metastasis.

Because these cells are believed to be at the root of the development and spread of cancer, they’re quickly becoming the center of cancer diagnostics and biomarkers. CSCs are resistant to a number of chemotherapy drugs and radiotherapy, and approximately 20 different strategies are currently being pursued in the hope of selectively targeting CSCs. This creates a huge opening for new companies and technologies dedicated to streamlining cellular research.

RBCC believes that the Bio-Assembler could allow researchers to dramatically shorten the development timeline for new CSC drugs and treatments, potentially proving very lucrative to the company.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Read more:
Cancer Stem Cell Research Drives Growth in RBCC’s Target Market